Premium
Effect of vitamin E and ticlopidine on platelet aggregation in Fabry's disease
Author(s) -
Sakuraba H.,
Igarashi T.,
Shibata T.,
Suzuki Y.
Publication year - 1987
Publication title -
clinical genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.543
H-Index - 102
eISSN - 1399-0004
pISSN - 0009-9163
DOI - 10.1111/j.1399-0004.1987.tb02820.x
Subject(s) - ticlopidine , medicine , platelet aggregation , platelet , vascular disease , disease , antiplatelet drug , fabry disease , atherosclerotic vascular disease , pharmacology , platelet adhesion , clopidogrel , aspirin
Thromboembolism, increased platelet aggregation and high plasma concentration of /?‐throm‐boglobulin were observed frequently in hemizygotes and heterozygotes of Fabry's disease. The administration of vitamin E and ticlopidine could improve the increased platelet aggregation in this disease. The platelet activation, probably induced by vascular endothelial damages, would accelerate atherosclerotic and thromboembolic vascular changes. Antiplatelet therapy will be effective for the prevention of these vascular complications in this disease.